Plasma PGE-2 levels and altered cytokine profiles in adherent peripheral blood mononuclear cells in non-small cell lung cancer (NSCLC).
| Autor: | Hidalgo GE; Division of Pulmonary and Critical Care Medicine, Lexington Veteran's Administration Medical Center, University of Kentucky, Chandler Medical Center, 800 Rose Street, Lexington, Kentucky 40536, USA. ghida2@pop.uky.edu, Zhong L, Doherty DE, Hirschowitz EA |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Molecular cancer [Mol Cancer] 2002 Nov 12; Vol. 1, pp. 5. Date of Electronic Publication: 2002 Nov 12. |
| DOI: | 10.1186/1476-4598-1-5 |
| Abstrakt: | Introduction: PGE-2 is constitutively produced by many non-small cell lung cancers (NSCLC) and its immunosuppressive effects have been linked to altered immune responses in lung cancer. We asked whether elevated levels of plasma PGE-2 correlated with monocyte IL10 production in the NSCLC environment. Looking for correlation in NSCLC patient blood we assayed plasma from NSCLC patients for PGE2 and IL10; we further evaluated production of IL10 by adherent mononuclear cells from a subset of these patients looking for an altered cytokine profile. Results: Our initial in vitro experiments show that monocyte IL10 induction correlates with tumor cell PGE-2 production, confirming similar reports in the literature. Data show plasma PGE-2 levels in 38 NSCLC patients are elevated compared to normal controls. Plasma IL10 levels were not significantly elevated; however, adherent monocytes derived from NSCLC patient blood did produce significantly more IL10 in 24 hr primary culture than those from normal controls (p < 0.01). The association of elevated plasma PGE-2 and monocyte derived IL-10 was not significant. Conclusions: Elevated plasma PGE-2 and monocyte IL10 production are associated with NSCLC. The biological significance to elevated PGE-2 levels in NSCLC are unclear. Further investigation of each as a nonspecific marker for NSCLC tumor is warranted. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|